STARPHARMA HOLDINGS LIMITED (SPL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
SPL - STARPHARMA HOLDINGS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.10
20 Dec |
0.000 OPEN $0.11 |
0.000 HIGH $0.11 |
210,851 LOW $0.10 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.0 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 8.3 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 6.8 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -7.0 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -98.50 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -25.95 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -24.14 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -18.37 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -25.95 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -40.57 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -7.1 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 23 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.39 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.1 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 1.07 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 1 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 22 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 16 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
SPL STOCK CHART
FNArena News on SPL
| 1 |
Australian Broker Call *Extra* Edition – Nov 14, 2022Nov 14 2022 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Sep 14, 2022Sep 14 2022 - Daily Market Reports |
| 3 |
Rudi’s View: August Results – First BloodAug 11 2022 - Rudi's View |
| 4 |
August In Review: Eleventh Month Of GainsSep 10 2021 - Australia |
| 5 |
February In Review: ASX Rises Five Consecutive MonthsMar 04 2021 - Australia |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
| 2 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |
| 3 |
Dr Boreham’s Crucible: Aroa BiosurgeryJul 29 2024 - Small Caps |
| 4 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
| 5 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
| 6 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
| 7 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Radiopharm TheranosticsJul 03 2024 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Amplia TherapeuticsJun 05 2024 - Small Caps |